⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2496092 | 0.77 | — | — | |
| SCHEMBL19360695 | 0.77 | — | — | |
| SCHEMBL392224 | 0.77 | — | — | |
| SCHEMBL2497209 | 0.73 | — | — | |
| SCHEMBL3430010 | 0.73 | — | — | |
| SCHEMBL617774 | 0.73 | — | — | |
| SCHEMBL790909 | 0.73 | TSHR (0.38) | — | |
| SCHEMBL18685580 | 0.73 | MMP8 (0.33) | — | |
| SCHEMBL2417317 | 0.73 | ADRB2 (0.42) | — | |
| SCHEMBL870738 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024036377-A1 | HAIRPIN OLIGONUCLEOTIDES | QUEENSLAND UNIVERSITY OF TECHNOLOGY (AU) | 2024-02-22 | — | — | WO | disclosed |
| EP-4267252-A1 | COMPOSITIONS AND METHODS OF USING PROGRAMMABLE NUCLEASES FOR INDUCING CELL DEATH | Mammoth Biosciences, Inc. (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-4192477-A1 | TREATMENT OF SKIN DISEASES AND DISORDERS USING INHIBITORS OF KALLIKREIN-RELATED PEPTIDASES (KLK) | Exicure Operating Company (US) | 2023-06-14 | — | — | EP | disclosed |
| WO-2022140572-A1 | COMPOSITIONS AND METHODS OF USING PROGRAMMABLE NUCLEASES FOR INDUCING CELL DEATH | MAMMOTH BIOSCIENCES, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| CN-110418647-A | The nucleic acid modifying enzyme and its application method of RNA guidance | UNIV CALIFORNIA | 2019-11-05 | — | — | CN | disclosed |
| CN-110023494-A | RNA-GUIDED NUCLEIC ACID MODIFYING ENZYMES AND METHODS OF USE THEREOF | 加利福尼亚大学董事会 | 2019-07-16 | — | — | CN | disclosed |
| CN-109641026-A | methods and compositions for detecting target RNA | 加利福尼亚大学董事会 | 2019-04-16 | — | — | CN | disclosed |
| CN-109476695-A | Method for determining RNA translation rate | 丹娜法伯癌症研究院 | 2019-03-15 | — | — | CN | disclosed |
| EP-3387127-A1 | ENZYMATIC REPLACEMENT THERAPY AND ANTISENSE THERAPY FOR POMPE DISEASE | Erasmus University Medical Center Rotterdam (NL) | 2018-10-17 | — | — | EP | disclosed |
| EP-2072496-B1 | METHOD FOR PRODUCING HIGH-PURITY QUATERNARY AMMONIUM SALT | OTSUKA CHEMICAL CO LTD (JP) | 2017-11-15 | — | — | EP | disclosed |
| WO-2004031350-A2 | MODULATION OF FORKHEAD BOX O1A EXPRESSION | AMGEN, INC. (US) | 2004-04-15 | — | — | WO | disclosed |
| WO-2004001061-A2 | ANTISENSE MODULATION OF HEME OXYGENASE 1 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2003-12-31 | — | — | WO | disclosed |
| WO-2003105754-A2 | ANTISENSE MODULATION OF VEGF-B EXPRESSION | ISIS PHARMACEUTICALS INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003105755-A2 | ANTISENSE MODULATION OF VEGF-C EXPRESSION | ISIS PHARMACEUTICALS INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003106645-A2 | ANTISENSE MODULATION OF SMRT EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| WO-2003104458-A1 | ANTISENSE MODULATION OF IL-1 RECEPTOR-ASSOCIATED KINASE-1 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2003-12-18 | — | — | WO | disclosed |
| WO-2003099224-A2 | ANTISENSE MOODULATION OF KINESIN-LIKE 1 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003100017-A2 | OLIGONUCLEOTIDES HAVING MODIFIED NUCLEOSIDE UNITS | ISIS PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003099840-A1 | OLIGONUCLEOTIDES HAVING MODIFIED NUCLEOSIDE UNITS | ISIS PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
| WO-2003095679-A1 | ANTISENSE MODULATION OF DYRK4 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2003-11-20 | — | — | WO | disclosed |